HCG: Dosing Protocols

Research Dosing Disclaimer#

The dosing information below is derived from research studies and is provided for educational purposes only. HCG is not approved for human use, and no official dosing guidelines exist.

Dose-Response Data#

We summarized dose–response evidence for human chorionic gonadotropin (hCG) across animal models, with body‑weight normalized dosing when available. A structured table of dosing regimens and outcomes is embedded below.

• Rats, chronic subcutaneous dosing (10, 50, 100 IU/kg): Adult male rats given hCG twice weekly for 3 months exhibited graded histological and hormonal responses. Ten IU/kg stimulated spermatogenesis (increased germ and Sertoli cells), whereas 50–100 IU/kg caused seminiferous epithelium damage (germ‑cell loss/exfoliation), interstitial edema, and marked Leydig cell hyperplasia/hypertrophy. Serum testosterone rose while LH/FSH were suppressed; changes were largely reversible within ~2 months after cessation (dose‑dependent severity).
• Rats, prepubertal intramuscular dosing (50 IU/kg every other day): Prepuberal Sprague–Dawley males treated 1–3 weeks showed a transient testis‑weight increase at week 1, progressive increases in plasma testosterone over time, Leydig cell hyperplasia, interstitial edema, and seminiferous epithelium deterioration; strong VEGF immunostaining in Leydig cells was observed (time‑course response at a single dose).
• Rats, postpubertal subcutaneous dosing (50 IU/kg, 3×/week, 10 weeks): In mature males, 50 IU/kg hCG increased serum testosterone and improved several hematologic indices compared with alcohol‑exposed animals; no multi‑dose series was tested.
• Goats, single intramuscular dose (25 IU/kg): Male Shiba goats (18–25 kg) receiving 25 IU/kg hCG had rapid increases in testicular blood flow (reduced Doppler RI/PI) and increased testis volume within ~1 hour; hormone changes correlated with blood‑flow metrics. Per‑animal exposure was ~450–625 IU based on reported body weight (single‑dose study).
• Rodent ovulation paradigms, absolute dosing: In immature female rats, low‑dose hCG (1.75 IU × 2 s.c.) alongside FSH, followed by a 35 IU i.p. trigger at 48 h, increased ovulated oocyte yield in a dose‑dependent manner relative to FSH alone and approached the effect of 10 IU PMSG; body‑weight normalization was not reported.
• Acute or assay‑level rat dosing: Acute i.p. “loading” doses up to 500 IU/kg have been used to elicit testosterone responses (details limited in excerpt); lower “sensitivity test” dosing at 5 IU/kg was used to demonstrate reduced Leydig responsiveness after EE2 exposure; an intermediate stimulation dose ~130 IU/kg was reported before Leydig cell isolation in a leptin/MSG model (assay contexts; not true multi‑dose series).

Unit conversions and body‑weight adjustment

• When studies report IU/kg, they already normalize to body weight. Where per‑animal IU can be inferred, we report it (e.g., goats 25 IU/kg × 18–25 kg ≈ 450–625 IU). Most rat studies did not report individual body weights, preventing per‑animal IU calculation; nevertheless, IU/kg allows interstudy comparison.
• Mass (µg) conversions were not reported in the excerpts; hCG potency varies by preparation, so direct IU→µg conversion is preparation‑specific and not inferable from these texts.

Study‑level evidence table

Synthesis and interpretation

• Testosterone and Leydig cell effects: Across rats, hCG reliably elevates serum testosterone with time‑dependent and dose‑related Leydig cell hyperplasia; at higher chronic doses (≥50 IU/kg), adverse seminiferous changes emerge, indicating a U‑shaped relationship for spermatogenesis (stimulation at 10 IU/kg, suppression at 50–100 IU/kg).

• Vascular/testicular hemodynamics: In goats, 25 IU/kg acutely increases testicular blood flow and volume within hours, linking steroidogenic activation with vascular responses.

• Ovulatory responses: In immature female rats, low‑dose hCG in concert with FSH augments ovulation yield, while a 35 IU i.p. hCG trigger induces ovulation; although IU/kg was not provided, the protocol demonstrates a dose‑responsive ovulatory effect of hCG within standard superovulation regimens.

• Assay contexts: High acute doses (e.g., 500 IU/kg) are used experimentally to maximize testosterone responses; very low doses (5 IU/kg) can interrogate receptor sensitivity following endocrine disruption.

• Several studies used a single dose level or absolute (per‑animal) doses without body‑weight reporting, limiting dose–response modeling across the full range of exposures. Mass‑based (µg/kg) data were not available in the provided excerpts and are preparation‑specific.

Animal studies show hCG exerts clear dose‑ and time‑dependent effects. In male rats, 10 IU/kg s.c. chronically stimulates spermatogenesis, whereas 50–100 IU/kg induces seminiferous injury with persistent Leydig activation; testosterone generally rises with hCG exposure. Single 25 IU/kg i.m. dosing in goats increases testicular perfusion and volume within an hour. In immature female rats, low‑dose hCG supports FSH‑driven ovulation and a 35 IU i.p. trigger reliably induces ovulation. These data provide dose‑normalized reference points (IU/kg) and observed outcomes relevant to designing or interpreting hCG experiments in animals.

Administration Routes#

We compared human chorionic gonadotropin (hCG) pharmacokinetics and bioavailability across subcutaneous (SC), intramuscular (IM), oral/sublingual, and topical routes using clinical and regulatory evidence. A concise comparison table is embedded.

Subcutaneous injection. After single SC administration, serum hCG rises to peak in roughly one day and clears over a week, with elimination half-life around 33–39 hours. In a randomized crossover PK study, urinary highly purified hCG (Choriomon®, 10,000 IU SC) achieved Cmax 337.9 ± 100.9 IU/L, median tmax 16 h, AUC0–∞ 23,779 ± 4,944 IU·h/L, t1/2 36.8 ± 5.1 h; recombinant hCG (Ovitrelle®, 250 µg ≈ 6500 IU SC) achieved Cmax 148.5 ± 36.5 IU/L, median tmax 24 h, AUC0–∞ 12,937.5 ± 2,723.4 IU·h/L, t1/2 38.6 ± 6.1 h. Dose-normalized exposure was ~20% higher and absorption faster for the urinary product; half-lives were similar (bioequivalence criteria not met for extent at these doses, but differences were judged not clinically relevant).

Intramuscular injection. In a randomized crossover study with direct SC versus IM sampling, IM injection yielded higher Cmax and AUC than SC overall; the difference was pronounced in obesity, where SC exposure was markedly reduced while IM exposure was preserved. In normal-weight women, median Cmax was ~291 mIU/mL (IM) vs ~142 mIU/mL (SC), and AUC ~9,586 vs ~4,152 mIU·h/mL; in obese women, median Cmax ~436 (IM) vs ~89 (SC) mIU/mL and AUC ~13,327 vs ~2,352 mIU·h/mL. Tmax typically occurred between 12–24 h for both routes in that sampling scheme. Historical matched‑dose data cited alongside SC PK indicate similar elimination half‑life (≈32–33 h) and broadly comparable exposure when dose and formulation are identical.

Oral and sublingual. No robust human pharmacokinetic evidence demonstrates measurable systemic exposure from oral/sublingual hCG products marketed for weight loss. A case of sublingual “hCG drops” had negative serum and urine qualitative tests; more broadly, regulatory and clinical reviews report a lack of efficacy evidence and challenge their legality and claims. Mechanistically, intact hCG (~36–40 kDa glycoprotein) is expected to have negligible oral bioavailability due to proteolysis and poor epithelial permeability.

Topical/transdermal. We found no human data showing systemic absorption of hCG from topical/transdermal products. Regulatory and professional reviews addressing non‑parenteral hCG products note lack of evidence and legal/marketing concerns, but do not report systemic PK. Mechanistically, the stratum corneum presents a formidable barrier to large proteins like hCG without specialized devices or potent enhancers; thus bioavailability is expected to be negligible. As context for non‑parenteral peptide delivery barriers, a rabbit rectal model required an absorption enhancer (α‑cyclodextrin) to achieve detectable plasma hCG and pharmacodynamic testosterone responses, underscoring size/enzymatic limitations across mucosae.

Regulatory perspective on OTC/homeopathic hCG. The FDA required decades ago that hCG labeling state it is not proven effective for obesity; in 2011, the FDA and FTC warned companies marketing “homeopathic/OTC hCG” for weight loss that they were selling unapproved drugs with unsupported claims. HCG is not listed in the Homeopathic Pharmacopeia of the U.S., so it cannot be legally marketed as a homeopathic agent. No agency communications provide positive evidence of oral/topical bioavailability; rather, they underscore lack of efficacy and regulatory noncompliance.

Conclusions. SC and IM injections reliably produce systemic exposure, with similar terminal half‑lives (~33–39 h). IM can yield higher early exposure (Cmax, AUC) compared with SC, particularly in individuals with higher adiposity, while historical matched‑dose data suggest SC and IM are broadly similar for extent when formulation and dose are the same. In contrast, oral/sublingual and topical routes lack demonstrated systemic bioavailability or pharmacologic effect in humans and are biologically implausible without absorption technologies; products marketed for weight loss via these routes have been rejected by regulators for unsupported claims.

Human-Equivalent Dosing#

Objective status update: We identified and synthesized the principal methods reported in the literature for translating animal doses to human‑equivalent doses (HED), and assessed how these apply to hCG, which is often dosed in IU rather than mg. No papers were found that directly provide IU‑to‑IU cross‑species scaling for hCG; instead, sources recommend converting IU to mass via product‑specific potency and using exposure/PD‑based approaches.

How animal study doses are scaled to human‑equivalent doses

1. Body surface area (BSA; Km) conversion

• Rule: Convert mg/kg to mg/m2 by multiplying by species Km, then scale between species; equivalently, HED (mg/kg) = Animal dose (mg/kg) × (Km_animal/Km_human). Typical Kms: mouse ≈ 3, rat ≈ 6, dog ≈ 20, human adult ≈ 37. This is the FDA‑endorsed conservative approach for deriving HED from NOAEL and informing MRSD after applying a safety factor (often ≥10).
• Example pattern: If a rat NOAEL is 10 mg/kg, HED ≈ 10 × (6/37) ≈ 1.62 mg/kg, then apply a safety factor for MRSD.

2. Weight‑based allometry using exponents

• Rule: HED (mg/kg) ≈ Animal dose × (W_animal/W_human)^(1−b), where b commonly 0.75 (metabolic) or 0.67 (surface‑area). Practical forms use exponents 0.25 or 0.33 on the weight ratio. Worked examples show large differences between 0.25 vs 0.33 assumptions.

3. PK‑parameter allometry (when PK available)

• Rule: Scale clearance approximately with BW^0.75 and volumes with BW^1; rate constants scale with BW^−0.25. Predict human CL and V, then simulate exposures to select human doses. This is standard for biologics and small molecules; for target‑mediated processes, mechanistic models may be needed.

4. Exposure matching (AUC/Cmax) to effect or NOAEL

• Rule: Choose human dose to match target AUC or Cmax associated with efficacy or NOAEL in animals, using predicted human CL from allometry or PBPK: Dose_human ≈ Target AUC × CL_human. Apply safety factors for first‑in‑human.

5. MABEL/PAD approaches and model‑based integration

• Concept: Use in vitro potency, receptor occupancy, and PK/PD modeling to identify the minimum anticipated biological effect level (MABEL) or PAD and derive a cautious starting dose. Particularly recommended for potent biologics and when exposure‑response is steep or non‑linear.

Application to hCG (human chorionic gonadotropin; IU‑based dosing)

• IU are bioactivity units defined against a reference standard and can vary in IU per mg across products. Direct IU‑to‑IU interspecies scaling is not recommended. Convert IU to mass using the product’s potency (IU/mg), then apply a scaling method (preferably exposure/PD matching or PK‑based allometry) to select a human dose, or use MABEL with in vitro LH receptor assays and PD biomarkers.
• For simple toxicology‑to‑HED translation when only dose (not exposure) is available, BSA (Km) scaling provides a conservative HED in mg/kg that can be back‑converted to IU using product potency; however, for a hormone like hCG with species‑specific PK and receptor biology, exposure/PD‑guided approaches are preferable.

Equations and example templates

• BSA/Km: HED (mg/kg) = Animal dose (mg/kg) × (Km_animal/Km_human); mg/m2 = mg/kg × Km. Example (rat→human): 10 mg/kg × (6/37) = 1.62 mg/kg.
• Weight‑based allometry: HED = Animal dose × (W_animal/W_human)^(1−b); examples commonly implement b = 0.75 (exponent 0.25) or b = 0.67 (exponent 0.33).
• PK allometry: CL_h = CL_a × (BW_h/BW_a)^0.75; V_h = V_a × (BW_h/BW_a)^1; then Dose_h ≈ Target AUC × CL_h.
• Exposure matching: Dose_h ≈ AUC_target × CL_human (AUC_target from animal efficacy or NOAEL); apply safety factor to determine MRSD.
• MABEL/PAD: Use in vitro potency (e.g., EC50), receptor occupancy and PK to find the minimal effect dose; apply safety factor to derive starting human dose.

Practical note for hCG conversions

• To translate an animal hCG dose reported in IU/kg to a human‑equivalent dose: (i) obtain the product‑specific potency (e.g., IU per mg) used in animals; (ii) convert IU/kg→mg/kg; (iii) perform HED scaling (BSA/Km or PK/exposure based); (iv) convert the resulting human mg/kg back to IU/kg using the intended clinical product’s potency if needed. Because different hCG preparations can have different IU/mg, exposure or PD matching is preferable when data allow.

Embedded reference table of methods

Limitations

• We did not identify a publication that specifically reports cross‑species IU‑based scaling examples for hCG; therefore, we recommend applying general biologic‑scaling methods and PD/exposure matching after converting IU to mass with product‑specific potency. This aligns with guidance cautioning against naïve dose scaling for biologics without PK/PD context.

Evidence Gaps#

• No human dose-finding studies have been completed
• Allometric scaling from animal models has inherent limitations
• Route-specific bioavailability data in humans is absent
• Optimal treatment duration has not been established

Related Reading#

• HCG overview and research guide
• HCG side effects profile
• HCG research evidence